The institutional cluster is directionally positive but small in scale and lacks insider corroboration. The primary catalyst is the upcoming PDUFA date for mitapivat in sickle cell disease (Nov 1, 2026). Monitor for additional institutional filings and insider buying ahead of the FDA decision; a positive outcome could drive significant upside, while a negative decision would likely reverse the recent gains.
Executive Summary
In Q2 2026, four institutional buyers accumulated $4.9M in AGIO while two sellers trimmed $1.2M, resulting in a net mixed cluster. The buying is dominated by Citigroup (doubled position to $3.3M) and Assenagon Asset Management (added to $3.9M), likely reacting to Agios' strong Q2 earnings beat (revenue up 259% YoY) and the FDA Priority Review for mitapivat in sickle cell disease. However, the cluster is small in absolute dollar terms relative to the $1.9B market cap, and the lack of insider buying (confluence score 11/100) weakens conviction. The net signal is modestly positive but not transformative.
Key Financial Metrics
Institutional Positions
Net institutional flow: $3.7M
▲ Buyers (4)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Assenagon Asset Management | ADD | +54.8% | $3.9M | $1.6M |
| Alps Advisors | ADD | +25.9% | $2.2M | $615.0K |
| Farther Finance Advisors | DOUBLED | +139.6% | $18.0K | $11.0K |
| Citigroup | DOUBLED | +421.6% | $3.3M | $2.7M |
▼ Sellers (2)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| New York State Common Retirement Fund | TRIM | -59.8% | $1.7M | -$978.5K |
| Td Asset Management | TRIM | -36.4% | $803.0K | -$243.0K |
Key Facts
- 4 institutional buyers added $4.9M in new AGIO positions in Q2 2026
- 2 institutional sellers trimmed $1.2M, led by New York State Common Retirement Fund (-$979K)
- Citigroup doubled its position (+421.6% shares) to $3.3M
- Assenagon Asset Management added 54.8% to a $3.9M position
- Cluster follows Agios' Q2 2026 earnings beat (revenue $44.7M, +259% YoY) and FDA Priority Review for mitapivat (PDUFA Nov 1, 2026)
- No insider open-market buying corroborates the institutional cluster (confluence score 11/100)
Financial Impact
4 institutional buyers accumulated $4.9M in new positions while 2 sellers trimmed $1.2M, net inflow of approximately $3.7M
Risk Factors
- Small cluster size ($4.9M buying vs $1.9B market cap) limits signal strength
- No insider buying to confirm institutional conviction
- Binary PDUFA risk on Nov 1, 2026 — a negative FDA decision would be severely bearish
- 13F data is 45+ days stale; positions may have been unwound
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-AGIO-2026-Q2 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 144 | $37.19 | awaiting T+60 | — | — |
Aug 6, 2026 11w ago | Institutional Cluster | $31.95 | awaiting T+60 | — | — |
Jul 30, 2026 12w ago | 8-K | $32.75 $37.00 | ▲ +12.98% | ▲ +10.51% | — |
Jul 30, 2026 12w ago | Press Release | $32.75 $37.00 | ▲ +12.98% | ▲ +10.51% | — |
Jul 7, 2026 15w ago | Press Release | $44.01 $33.25 | ▼ −24.45% | ▼ −26.44% | — |
Jun 29, 2026 17w ago | Press Release | $38.04 $34.97 | ▼ −8.07% | ▼ −12.46% | — |
Jun 18, 2026 18w ago | 8-K | $35.10 $32.81 | ▼ −6.52% | ▼ −8.27% | — |
Jun 13, 2026 19w ago | Press Release | $31.82 $34.63 | ▲ +8.83% | ▲ +7.83% | — |
Jun 1, 2026 21w ago | Press Release | $28.00 $33.90 | ▲ +21.07% | ▲ +19.84% | — |
May 29, 2026 21w ago | Press Release | $29.40 $32.64 | ▼ −11.02% | ▼ −9.84% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers